Changes/additions to materials:

MeReC Stop Press on NICE Clinical Guideline 67. 

NICE issued guidance on CV risk assessment and lipid modification in June 2008. The important changes are discussed in the MeReC Stop Press, which should be read in conjunction with the materials in this room of NPCi.

MHRA advice re fibrates - Drug Safety Update Vol 1, Issue 4. 4th. November 2007

The MHRA has issued revised advice to prescribers concerning the place in therapy of fibrates:
"Fibrates should be used as first-line therapy only in patients with isolated severe hypertriglyceridaemia. In patients who also have raised cholesterol, fibrates may be considered only when a statin or other effective treatments are contraindicated or not tolerated".

This is discussed in a MeReC Stop Press, which should be read in conjunction with the materials in this room of NPCi.

Note that some of the materials apply the black triangle (▼) to rosuvastatin. This was correct at their time of publication but the black triangle was removed by the MHRA in June 2007

A guide to the support materials for this topic is available in the library.

Work through the case study below to test your knowledge on Lipids. The answers given within this case study are model answers and not the only correct answer.